 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Metabolic Complications: Research
See also: Lipodystrophy Basics
2002
- Research From the 42nd ICAAC: High Lopinavir Levels Predict High Lipids (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Cost-Effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults (November 25, 2002)
A study asserts that, generally speaking, the risks of lipodystrophy and heart disease are outweighed by the benefits of early HIV treatment.
In Archives of Internal Medicine - National Institutes of Health Awards $1.95 Million to Study New Treatments for Drug Side Effects (November 22, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Study Finds Protease Inhibitors May Help Cause Lipodystrophy (October 30, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Evaluation of Coronary Artery Calcification by Electron Beam Computed Tomography in HIV-Infected Men Receiving Prolonged Protease Inhibitor Therapy (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - Study Reports Self-Image Concerns in HIV-Positive People With Lipodystrophy (October 22, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - HIV Positive May Risk Death to Avoid Side Effect of Meds (October 2, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - The Case Against Zerit (October 2002)
Research increasingly points to NRTIs -- particularly d4T -- as a likely culprit in metabolic disorders.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Overview of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Lack of Recurrence of Symptomatic and Asymptomatic Hyperlactatemia When Stavudine Is Replaced by Either Abacavir or Zidovudine: 48-Week Data (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - The Viramune Hepatic Safety Project: Analysis of Symptomatic Hepatic Events (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Twelve Weeks of Atazanavir Treatment Reverses Nelfinavir-Associated Hyperlipidemia: Results From BMS AI424-044 (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - The Mechanisms of Lipodystrophy: Leptin, Lipodystrophy and Insulin Resistance; Treatment of Non-HIV Lipodystrophy With Thiazolidinediones and Leptin (September 23, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Cancer Drug for Male Breast Enlargement? (September 18, 2002)
From Canadian AIDS Treatment Information Exchange - Lactic Acidosis: Watching and Waiting (September 2002)
Metformin (glucophage), used to treat diabetes, may add to the lactic acidosis risk posed by some antiretrovirals.
In HIV Treatment ALERTS!, from The Center for AIDS - Metabolic and Body Composition Changes in Patients Switching From a Protease Inhibitor-Containing Regimen to Abacavir, Efavirenz or Nevirapine; Twelve-Month Results of a Randomized Study (LIPNEFA) (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO - Fat Redistribution and Metabolic Changes With a Nucleoside-Reverse Transcriptase Inhibitor, Non-NRTI, or Protease Inhibitor-Based Regimen: FRAMS Substudy of the Atlantic Study (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO - Disturbing Metabolic Disturbances: Basic Science (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Disturbing Metabolic Disturbances: Clinical Impact (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Quantification of Mitochondrial DNA in Human Cells Using Real-Time PCR With Fluorogenic Reporters (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Special Retrovirus Update: Lipodystrophy (March 28, 2002)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project - Lipoatrophy and Antiretroviral Drug Changes (March 8, 2002)
In AIDS Treatment News, from AIDS Treatment News - 9th Retrovirus Conference Coverage: Lipodystrophy Definition (Spring 2002)
In STEP Perspective, from Seattle Treatment Education Project - 9th Retrovirus Conference Coverage: Lipodystrophy Treatment (Spring 2002)
In STEP Perspective, from Seattle Treatment Education Project - 9th Retrovirus Conference Coverage: Lipodystrophy: To Switch or Not to Switch? (Spring 2002)
In STEP Perspective, from Seattle Treatment Education Project - Lipodystrophy Update (March 2002)
To read PDF, click here
In Project Inform Perspective, from Project Inform - A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Combivir/Abacavir/Nelfinavir, or Stavudine/Lamivudine/NFV (ESS40002) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Switching Stavudine or Zidovudine to Abacavir for HIV Lipoatrophy: A Randomized, Controlled, Open-Label, Multicentre, 24-Week Study (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Lipodystrophy Treatment After Barcelona Conference: Interview With Howard Grossman, M.D.
From AIDS Treatment News
  |
  |